A5015274804- Chronic Lymphocytic Leukemia Research
- COVID-19 and healthcare impacts
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Breast Cancer Treatment Studies
- Acute Myeloid Leukemia Research
- Global Cancer Incidence and Screening
- Healthcare cost, quality, practices
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Public Health and Environmental Issues
- Lung Cancer Research Studies
- Scarabaeidae Beetle Taxonomy and Biogeography
- Melanoma and MAPK Pathways
- COVID-19 Clinical Research Studies
- Plant and soil sciences
- Antifungal resistance and susceptibility
- Immunodeficiency and Autoimmune Disorders
- Cancer Diagnosis and Treatment
Hospital Militar Central
2021-2024
Asociación Colombiana de Gastroenterología
2019-2024
Institute of Cardiology
2018-2024
Asociación Colombiana de Hematología y Oncología
2019-2023
Sociedad Española de Cardiología
2023
Colombian Association of Surgery
2021
The ACHOCC-19 study was performed to characterize COVID-19 infection in a Colombian oncological population.
Multiple Myeloma (MM) is a plasma cell derived clonal disorder that represents around 1% of all newly diagnosed neoplasms. Limited data regarding MM treatment in Latin America available, and access to novel agents for substantial portion the population limited by their high costs.RENEHOC bidirectional (retrospective prospective) multicenter observational registry hematological malignancies Colombia. patients included up July 2020 were analyzed on this report.890 are reported with median...
To describe the population with early malignant melanoma, we performed a cohort study on basis of Epidemiological Registry Malignant Melanoma in Colombia-Asociacion Colombiana de Hematologia y Oncologia. From January 2011 until December 2021, 759 patients were included; average age was 66 years, 57% women, acral lentiginous histology found 27.8% patients, and median follow-up 36.5 months. The prognostic factors for overall survival our are Eastern Cooperative Oncology Group 3-4 (hazard ratio...
Abstract Introduction: Breast cancer (BC) is the most frequent neoplasm in Colombia. In contrast to high-income countries, expected 5-year overall survival (OS) remains below 80% over last years. Neoadjuvant chemotherapy (NACT) has reduced risk of relapse and death by achieving higher pathological complete response (ypCR) rates, but delays dose reductions could impact prognosis negatively. We have previously reported outcomes NACT from a real-world multicenter historical cohort Colombian...
e21530 Background: The features and prognostic factors of patients with metastatic malignant melanoma are not well established in our country. Our objective is to collect analyze the characteristics a cohort Colombian patients. Methods: Analytical study based on Epidemiologic Registry Malignant Melanoma Colombia (REMMEC). Data were collected between January 2011 December 2023. Patients older than 18 years confirmed diagnosis advanced included. Descriptive analysis demographic clinical...
PURPOSE Breast cancer (BC) is the most frequent neoplasm in women Colombia and associated with a higher mortality rate than other countries regions. Neoadjuvant chemotherapy (NACT) has become standard treatment locally advanced BC provides an opportunity to improve clinical outcomes BC. This study aims describe characteristics, patterns, after NACT cohort of Colombian patients METHODS We performed retrospective study. included adult treated NACT. Clinical charts were retrospectively...
Nivolumab is a human programmed death receptor-1 blocking antibody, used as treatment option in patients with advanced non-small-cell lung cancer (NSCLC). We assessed the nivolumab efficacy terms of survival and response to second-line (2L) or third-line (3L) therapy NSCLC. This multicentric observational study. Data NSCLC who received 2L 3L were analyzed retrospectively. Information regarding patient demographics clinical backgrounds, patterns from diagnosis post-nivolumab treatment,...
Introducción: dentro de los subtipos linfoma, el linfoma células del manto o anteriormente denominado linfocítico intermedio corresponde a 3-10% no Hodgkin B. El tratamiento se enfoca según la clasificación paciente, edad, estado funcional y comorbilidades, lo cual está directamente relacionado con capacidad recibir un intensivo trasplante. Es importante homogeneizar conductas fin ofrecer las mejores alternativas bajo contexto colombiano, pues actualmente existen diferentes opciones...
Introduction:During the pandemic, it has been recommended that vaccination against COVID-19 be a priority for patients with cancer; however, these were not included in initial studies evaluating available vaccines.Objective: To define impact of preventing risk complications associated infection cohort cancer Colombia.Methods: An analytical observational study, based on national registry and COVID 19 ACHOC-C19, was done.The data collected from June 2021, until October 2021.Inclusion criteria...
Background: Multiple myeloma (MM) represents 1% of all newly diagnosed neoplasms, Autologous Stem Cell Transplantation (ASCT) has become the standard care for fit MM patients after completion induction therapy. Maintenance treatment transplant also proven to positively impact event free survival in multiple clinical trials. Aims: RENEHOC is a multicenter database established January 2018. Its primary aim provide local information on diagnosis, and outcomes other hematologic Colombia. This...
Abstract Introduction Breast cancer (BC) is the most frequent neoplasm in Colombia, with mortality rate increasing past decade. The expected 5-year overall survival (OS) < 80%, being Latin American country worst prognosis. 2 factors related to this are higher frequency of advanced stages and aggressive tumor subtypes.Neoadjuvant chemotherapy (NACT), ypCR, have demonstrated impact on risk relapse death. This trial describes characteristics, treatment patterns, clinical outcomes, ypCR...
e18806 Background: According to results of previous ACHOC-C19 study, mortality in patients with cancer and COVID 19 infection Colombia is 26%. The impact vaccination was not evaluated prior the implementation this strategy worldwide cancer. We aimed characterize SARSCOV 2 a local cohort vaccinated oncologic patients. Methods: ACHOCC-19 VAC registry national multi-center observational study. Data were collected between April 2021 March 2022. Inclusion criteria were: age more than 18 years,...
Objetivos: el nivolumab es un anticuerpo monoclonal contra PD-L1 (programmed death receptor-1) usado como opción terapéutica en pacientes con cáncer de pulmón células no pequeñas (CPCNP) avanzado. Este estudio tuvo objetivo evaluar la experiencia segunda (2L) y tercera línea (3L) tratamiento CPCNP avanzado, diferentes centros oncológicos Colombia.
Introducción: el HCC es una enfermedad neoplásica de baja frecuencia en Colombia (2 % las enfermedades neoplásicas) y explica 4 muertes asociadas a cáncer. El tratamiento del se basa la posibilidad realizar resección quirúrgica o trasplante hígado, sin embargo, tasa donación órganos sigue siendo (8 donantes/millón habitantes), por lo cual, pueden utilizar opciones terapia locoregional como ablación con radiofrecuencia (RFA), DEB-TACE terapias puente hasta un para intermedio. estudio ICAROS...
Introducción: Según GLOBOCAN 2020 a nivel mundial, el cáncer de pulmón (CP) fue 2° más incidente (2.2 millones nuevos casos), y la principal causa mortalidad por cáncer, con 1.8 muertes. En Colombia, CP es 5° incidencia 4° muerte demostrando una brecha – que refleja mal pronóstico enfermedad. La mayoría los se diagnostican en estadios avanzados; sin embargo, compromiso metastásico ojo muy infrecuente (6-9% las metástasis), siendo casos coroideo (80%), comprometiendo severamente funcionalidad...
Introducción: el cáncer de pulmón (CP) es quinto más incidente y la cuarta causa mortalidad por en Colombia. En los últimos años desarrollo terapias dirigidas a mutaciones activadoras del CP han significado un cambio paradigma tratamiento, con impacto significativo mortalidad. El alectinib inhibidor potente altamente selectivo ALK, remarcables tasas respuesta (hasta 85 %); sin embargo, estudios aprobación incluyeron solo pacientes ECOG= 2, administrado cápsulas vía oral, lo cual limita uso...
Objetivos: el cáncer de mama (CM) es la neoplasia más frecuente en Colombia. La supervivencia global a 5 años <80 %, siendo país latinoamericano con peor pronóstico. Las estrategias preventivas como identificación población riesgo síndrome CM y ovario hereditario (HBOC), tiene potencial reducir incidencia disminuir los diagnósticos estadios avanzados. mayoría estudios publicados colombiana, han evaluado variantes reportadas fundadoras, denominadas “Perfil Colombia” o seleccionada alta...